WASHINGTON – The Food and Drug Administration has canceled a meeting to review Eli Lilly’s antidepressant Cymbalta for a new use against chronic pain.
Read this article:
FDA cancels meeting to review Lilly’s antidepressant as a new pain treatment (Minneapolis-St. Paul Star Tribune)
